Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. [electronic resource]
Producer: 20060413Description: 1612-9 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antineoplastic Agents -- therapeutic use
- Class I Phosphatidylinositol 3-Kinases
- ErbB Receptors -- antagonists & inhibitors
- Esophageal Neoplasms -- drug therapy
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Female
- Gefitinib
- Gene Dosage
- Genes, ras
- Humans
- Male
- Middle Aged
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphorylation
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinazolines -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.